ExpreS2ion Biotech Holding AB (SE:EXPRS2)
:EXPRS2
Top Page
ExpreS2ion Biotech Holding AB
(EXPRS2)
Select Model
Select Model
Rating:40Underperform
Price Target:
kr6.50
▼(-61.99% Downside)
Action:ReiteratedDate:03/27/26
The score is primarily constrained by weak financial performance (recurring losses and ongoing cash burn despite low leverage) and very bearish technicals (price far below key moving averages with negative momentum). Valuation contributes limited support because the negative P/E reflects loss-making operations and dividend yield data is unavailable.
Positive Factors
Proprietary ExpreS2 platform
ExpreS2's proprietary insect-cell expression technology is a durable competitive asset: it enables production of complex antigens and VLP components that are hard to replicate, supports repeatable service contracts, and makes the company a sought partner for vaccine and protein developers over the medium term.
Negative Factors
Persistent operating losses
Sustained operating and net losses mean the business consumes capital rather than generating it. Over the medium term this forces dependence on external funding, constrains strategic investments, and increases risk that programs or service growth cannot be financed internally.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary ExpreS2 platform
ExpreS2's proprietary insect-cell expression technology is a durable competitive asset: it enables production of complex antigens and VLP components that are hard to replicate, supports repeatable service contracts, and makes the company a sought partner for vaccine and protein developers over the medium term.
Read all positive factors
ExpreS2ion Biotech Holding AB (EXPRS2) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr24.68M
Dividend YieldN/A
Average Volume (3M)19.88K
Price to Earnings (P/E)―
Beta (1Y)1.57
Revenue Growth8.46%
EPS Growth11.73%
CountrySE
Employees20
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.41
Shares Outstanding3,530,233
10 Day Avg. Volume26,629
30 Day Avg. Volume19,883
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)1.27
Price to Sales (P/S)12.37
P/FCF Ratio-1.11
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-27
Revenue Forecast (FY)kr10.00M
ExpreS2ion Biotech Holding AB Business Overview & Revenue Model
Company Description
ExpreS2ion Biotech Holding AB (publ), through its subsidiary, ExpreS2 ion Biotechnologies ApS, develops and produces complex proteins for vaccines and diagnostics in Denmark. The company develops capsid virus-like particle COVID-19 vaccine, which ...
How the Company Makes Money
The company makes money primarily through (1) commercial/research services based on its ExpreS2 protein production platform and (2) monetization of its own and partnered development programs when they generate proceeds.
Key revenue streams:
- Pla...
ExpreS2ion Biotech Holding AB Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
58
Neutral
Cash Flow
20
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 3.66M | 3.01M | 7.05M | 5.09M | 12.23M |
| Gross Profit | -42.84M | -2.67M | 3.40M | 5.00K | 4.72M |
| EBITDA | -51.35M | -64.34M | -102.45M | -124.49M | -46.38M |
| Net Income | -38.09M | -36.04M | -91.40M | -118.61M | -43.92M |
Balance Sheet | |||||
| Total Assets | 65.11M | 104.53M | 78.69M | 137.36M | 151.96M |
| Cash, Cash Equivalents and Short-Term Investments | 47.55M | 81.54M | 57.60M | 110.97M | 138.88M |
| Total Debt | 2.21M | 1.80M | 1.71M | 1.85M | 2.11M |
| Total Liabilities | 29.42M | 40.11M | 13.33M | 34.04M | 11.61M |
| Stockholders Equity | 35.69M | 64.80M | 65.36M | 103.33M | 140.35M |
Cash Flow | |||||
| Free Cash Flow | -40.90M | -34.80M | -102.90M | -100.00M | -46.36M |
| Operating Cash Flow | -40.90M | -33.93M | -100.89M | -99.61M | -45.65M |
| Investing Cash Flow | 0.00 | 21.27M | -2.02M | 105.33M | -100.92M |
| Financing Cash Flow | 10.78M | 34.87M | 47.84M | 61.46M | 74.55M |
ExpreS2ion Biotech Holding AB Technical Analysis
Neutral
17.10
Price Trends
10.63
Negative
13.55
Negative
17.86
Negative
Market Momentum
-1.10
Negative
47.23
Neutral
77.83
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:EXPRS2, the sentiment is Neutral. The current price of 17.1 is above the 20-day moving average (MA) of 5.41, above the 50-day MA of 10.63, and below the 200-day MA of 17.86, indicating a neutral trend. The MACD of -1.10 indicates Negative momentum. The RSI at 47.23 is Neutral, neither overbought nor oversold. The STOCH value of 77.83 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SE:EXPRS2.
ExpreS2ion Biotech Holding AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | kr263.79M | 1.48 | -264.12% | ― | -17.80% | -11.96% | |
52 Neutral | kr64.55M | -4.39 | -79.59% | ― | 59.70% | 44.60% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | kr80.07M | -5.14 | -202.18% | ― | ― | 20.55% | |
47 Neutral | kr12.23M | -1.92 | -84.80% | ― | ― | 64.02% | |
43 Neutral | kr41.38M | -1.97 | ― | 8.47% | -94.12% | -25.83% | |
40 Underperform | kr24.68M | -1.19 | -88.65% | ― | 8.46% | 11.73% |
* Healthcare Sector Average
SE:EXPRS2
ExpreS2ion Biotech Holding AB
6.99
-11.45
-62.09%
SE:ONCOZ
OncoZenge AB
5.70
1.40
32.40%
SE:STABL
Stayble Therapeutics AB
0.19
-0.25
-57.21%
SE:LARK
CombiGene AB
2.09
-0.04
-1.65%
SE:SPRINT
Sprint Bioscience AB
2.50
1.81
262.32%
SE:ACOU
AcouSort AB
3.05
-0.72
-19.10%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.